A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Local Institution
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1
- Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting
- Participants must have an ECOG performance status of less than or equal to 1
- Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1
Exclusion Criteria:
- Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
- Participants with prior exposure to anti PD-1 or anti-PDL1 therapy
- Participants must not have a history of allergy to any of the study treatment components
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental Arm A
2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
|
Specified Dose on Specified Day
Specified Dose on Specified Day
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The Number of Participants Experiencing Adverse Events (AE)
Prazo: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing adverse events (AEs) to assess the safety and tolerability of BMS-986205. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
|
The Number of Participants Experiencing Serious Adverse Events (SAE)
Prazo: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing serious adverse events (SAEs) to assess the safety and tolerability of BMS-986205 Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
|
The Number of Participants Experience Adverse Events (AE) Leading to Discontinuation
Prazo: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing adverse events (AEs) leading to discontinuation to assess the safety and tolerability of BMS-986205 An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
|
Number of Participant Deaths
Prazo: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants who died in each arm during the study to assess the safety and tolerability of BMS-986205.
|
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
|
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
Prazo: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units to assess the safety and tolerability of BMS-986205. The number of participants with the following laboratory abnormalities will be summarized: ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN Total bilirubin > 1.5 x ULN and 2 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN with total bilirubin > 2 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN with total bilirubin > 2 x ULN |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
|
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
Prazo: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants with clinical laboratory test abnormalities based on US conventional units to assess the safety and tolerability of BMS-986205. The number of subjects with the following laboratory abnormalities will be summarized: TSH > ULN WITH TSH <= ULN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) TSH < LLN WITH TSH >= LLN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
|
(Cmax) Maximum Observed Plasma Concentration
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The maximum observes plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
|
(Tmax) Time of Maximum Observed Plasma Concentration
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The time of maximum observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
|
(AUC(TAU)) Area Under the Concentration-time Curve in One Dosing Interval
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The area under the concentration-time curve in one dosing interval was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
|
(CLT/F) Apparent Total Body Clearance
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1
|
The apparent total body clearance was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1
|
|
(T-HALF (Eff, AUC)) Effective Elimination Half-life
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The effective elimination half-life was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
T-HALF (eff, AUC) explains the degree of AUC accumulation observed.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
|
(AI_CMAX) Accumulation Index
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
AI is calculated based on ratio of Cmax at steady state to after the first dose.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
|
(AI_AUC ) Accumulation Index
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
AI is calculated based on ratio of AUC(TAU) at steady state to after the first dose.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
|
(Ctrough) Trough Observed Plasma Concentration
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1
|
The trough observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1
|
|
(percentUR24) Percent Urinary Recovery Over 24 Hours
Prazo: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2
|
The percent urinary recovery over 24 hours was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab. BMS-986205 had minimal evaluable concentration in urine to derive the parameter. |
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR)
Prazo: From first dose up to approximately 2 years
|
ORR is defined as the total number of participants whose best overall response (BOR) is either a completer response (CR) or partial response (PR) divided by the total number of participants in the population of interest. Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator BOR is defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. |
From first dose up to approximately 2 years
|
|
Best Overall Response (BOR)
Prazo: From first dose up to approximately 2 years
|
BOR defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy.
Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator
|
From first dose up to approximately 2 years
|
|
Duration of Response (DOR)
Prazo: From first dose up to approximately 2 years
|
Duration of Response (DOR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first.
Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator.
|
From first dose up to approximately 2 years
|
|
Measurement of Serum Kynurenine Levels
Prazo: Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of kynurenine levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
|
Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
|
Measurement of Tryptophan Levels
Prazo: Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of tryptophan levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
|
Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
|
Number of Participants With Anti-drug Antibodies (ADA) to Nivolumab
Prazo: Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)
|
The number of participants with positive or negative anti-drug antibodies (ADA) to nivolumab was collected to characterize the immunogenicity of nivolumab when administered in combination with BMS-986205. Baseline ADA Positive: A subject with baseline ADA-positive sample. ADA Positive: A subject with at least one ADA-positive sample relative to baseline. Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline ADA Negative: A subject with no ADA-positive sample after initiation of treatment. |
Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CA017-076
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .